Our research lab at The Ohio State University within the Division of Hematology focuses on the molecular characterization and therapeutic targeting of initiating cells, hematopoietic stem cells and the tumor micro-environment associated accessory cells. We seek to understand the basic underlying mechanisms of stem cell biology and how these are perturbed in hematological malignancies, such as Lymphoma, Leukemia and Multiple Myeloma.
The Sehgal lab focuses on the molecular/genomic characterization and therapeutic targeting of Lymphoma stem cells in human hematologic malignancies, particularly B-cell Lymphoma. Our research is focused on the molecular characterization and therapeutic targeting of initiating cells, hematopoietic stem cells and tumor microenvironment associated accessory cells. Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of lymphoma stem cell behavior. We seek to understand the basic underlying mechanisms of stem cell biology and how these are perturbed in hematological malignancies, such as Lymphoma, Leukemia and Multiple Myeloma. Read more
We are interested to understand how FMS-like Tyrosine Kinase regulates Hematopoiesis and stem cell autonomy. We are actively developing lineage-specific inducible knockout mice. This model will help us dissect the role of FMS-like Tyrosine Kinase in Normal and Malignant Hematopoiesis. A major advantage of this model is its improved sensitivity, which allows it to detect subtle dynamic changes in response to our experimentation.
Tumor Initiating Stem Cell
Previously we have identified that the sub-population of Mantle-Cell lymphoma is capable of generating the terminally differentiated/mature tumor cells. We are now focusing on the molecular characterization and therapeutic targeting of initiating/stem cells in human hematologic malignancies, particularly Mantle-Cell Lymphoma along with Dr. Baiocchi and Dr. Alinari.
Mimicking Tumor Microenvironment
In an effort to gain a better understanding of how the bone marrow influences the survival of lymphoma cells we have developed an ex-vivo culture system and organoids, we have recently begun to develop new humanized bone patient-derived xenograft to investigate the role of bone marrow niche in tumor survival.
Dr. Leonard Lalit Sehgal, M.Phil, Ph.D.
Dr. Lalit Sehgal received his MS in Molecular and Human Genetics, and his Ph.D. under the mentorship of Dr. Sorab Dalal. He completed a postdoctoral fellowship in B-cell Lymphoma with Dr. Felipe Samaniego at the University of Texas MD Anderson Cancer Center, TX.
Anuvrat Sircar, MS
Anuvrat Sircar received his MS in Biotechnology and is currently a Graduate student in the Molecular, Cellular and Developmental Biology graduate program at The Ohio State University. He is interested in understanding the role of the tumor micro-environment in Mantle-Cell Lymphoma.
Get to Know Us
Dr. Satish Singh, Ph.D.
Dr. Satish Singh received his MS in Virology and recently completed his Ph.D. in Molecular and Cellular Biology from the Tata Memorial Center, Mumbai. He is currently working to identify novel therapeutic targets and screening novel small molecule inhibitors, targeting FMS-like tyrosine kinase for relapsed/refractory Mantle-Cell Lymphoma and Acute Myeloid Leukemia.
Amber Hart, BS
Amber completed her Bachelor of Science in Molecular Genetics at the Ohio State University. She is currently working on the mutational landscape of tumor suppressor proteins such as p53 in MCL, and the interplay of key factors which regulate apoptosis. Her keen interest lies in how the tumor cells are able to efficiently evade apoptosis and gain resistance to current therapies. By elucidating the signaling pathways utilized by the tumors to facilitate survival, Amber’s greater interest lies in the search for putative druggable candidates against MCL.
Dr. Sayan Mullick-Chowdhury, Ph.D.
Sayan Mullick Chowdhury completed his Ph.D. in Molecular and Cellular Biology at Stony Brook University, NY. He continued his postdoctoral research at Stanford Univerity, CA, in the Department of Radiology. He is currently developing a humanized micro-environment for evaluating hematological malignancies in small animals and elucidating the role of FMS-like tyrosine kinase in lymphoma pathogenesis and resistance.
Connor is currently a senior majoring in Microbiology at The Ohio State University. He is currently working on gaining undergraduate research experience by developing a novel screening system to test drug resistance constructs using Crispr/Cas9 system.
The Fruits of Our Labor
Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid. Leukemia. 2018 Jun 28. doi: 10.1038/s41375-018-0192-z. https://www.nature.com/articles/s41375-018-0192-z
Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2018 Mar;32(3):663-674. https://www.nature.com/articles/leu2017215
Inhibition Of Demethylase KDM6B Sensitizes Diffuse Large B-Cell Lymphoma To Chemotherapeutic Drugs. Haematologica. 2017 Feb;102(2):373-380. http://www.haematologica.org/content/102/2/373.long
LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 2016 Dec 20;14(1):346. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-1100-9
Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015 Jun 6;8:63. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-015-0161-1
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. 2014 Dec;28(12):2376-87. https://www.nature.com/articles/leu2014126
We are always looking for talented undergraduate students, visiting fellows, and postdoctoral researchers to join our team. Graduate students from the MCDB program are invited to rotate in the lab. Staff positions are posted separately when opened.